title: Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2.
abstract: Diverse proteases cleave protease-activated receptor-2 (PAR2) on primary sensory neurons and epithelial cells to evoke pain and inflammation. Trypsin and tryptase activate PAR2 by a canonical mechanism that entails cleavage within the extracellular N-terminus revealing a tethered ligand that activates the cleaved receptor. Cathepsin-S and elastase are biased agonists that cleave PAR2 at different sites to activate distinct signalling pathways. Although PAR2 is a therapeutic target for inflammatory and painful diseases, the divergent mechanisms of proteolytic activation complicate the development of therapeutically useful antagonists.
  
  
  
  We investigated whether the PAR2 antagonist GB88 inhibits protease-evoked activation of nociceptors and protease-stimulated oedema and hyperalgesia in rodents.
  
  
  
  Intraplantar injection of trypsin, cathespsin-S or elastase stimulated mechanical and thermal hyperalgesia and oedema in mice. Oral GB88 or par2 deletion inhibited the algesic and proinflammatory actions of all three proteases, but did not affect basal responses. GB88 also prevented pronociceptive and proinflammatory effects of the PAR2-selective agonists 2-furoyl-LIGRLO-NH2 and AC264613. GB88 did not affect capsaicin-evoked hyperalgesia or inflammation. Trypsin, cathepsin-S and elastase increased [Ca(2+) ]i in rat nociceptors, which expressed PAR2. GB88 inhibited this activation of nociceptors by all three proteases, but did not affect capsaicin-evoked activation of nociceptors or inhibit the catalytic activity of the three proteases.
  
  
  
  GB88 inhibits the capacity of canonical and biased protease agonists of PAR2 to cause nociception and inflammation.
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.
authors.forename: T
authors.initials: T
authors.lastname: Lieu
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.
authors.forename: E
authors.initials: E
authors.lastname: Savage
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Zhao
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Edgington-Mitchell
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.
authors.forename: N
authors.initials: N
authors.lastname: Barlow
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Bron
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.|Departments of Anatomy and Neuroscience, University of Melbourne, Melbourne, Australia.
authors.forename: D P
authors.initials: DP
authors.lastname: Poole
authors.affiliation: Takeda Pharmaceuticals, Zurich, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: McLean
authors.affiliation: Centre for Inflammation and Disease Research and Centre for Pain Research, Institute of Molecular Bioscience, University of Queensland, Brisbane, Australia.|Australian Research Council Centre of Excellence in Advanced Molecular Imaging, University of Queensland, Brisbane, Australia.
authors.forename: R-J
authors.initials: RJ
authors.lastname: Lohman
authors.affiliation: Centre for Inflammation and Disease Research and Centre for Pain Research, Institute of Molecular Bioscience, University of Queensland, Brisbane, Australia.|Australian Research Council Centre of Excellence in Advanced Molecular Imaging, University of Queensland, Brisbane, Australia.
authors.forename: D P
authors.initials: DP
authors.lastname: Fairlie
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.|Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Australia.|Departments of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia.
authors.forename: N W
authors.initials: NW
authors.lastname: Bunnett
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D007249:Inflammation / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009619:Nociceptors / Q000378:metabolism*; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044464:Receptor, PAR-2 / Q000819:agonists* / Q000172:deficiency / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: C581100:GB88 compound; D009842:Oligopeptides; D044464:Receptor, PAR-2